Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
| ▸ | SLC22A4 | Q9H015 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1331030 | 1.00 | POLB (0.49) | POLBALPLALPGSLC22A4GAA | |
| SCHEMBL2926302 | 0.86 | POLB (0.36) | POLBALPLALPGSLC22A4GAA | |
| SCHEMBL19421166 | 0.86 | POLB (0.36) | POLBALPLALPGSLC22A4GAA | |
| SCHEMBL19421167 | 0.78 | — | — | |
| Histidine SCHEMBL8161511 | 0.76 | CYP3A4 (0.33) | — | |
| Histidine SCHEMBL3739430 | 0.74 | CYP3A4 (0.32) | — | |
| Histidine SCHEMBL11881302 | 0.74 | CYP3A4 (0.32) | — | |
| Histidine SCHEMBL8161515 | 0.74 | CYP3A4 (0.32) | — | |
| Histidine SCHEMBL17473905 | 0.74 | CYP3A4 (0.32) | — | |
| Histidine SCHEMBL951652 | 0.74 | CYP3A4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167490-B2 | Ergothioneine production through metabolic engineering | ERGO HEALTH LLC (US) | 2019-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167490-B2 | Ergothioneine production through metabolic engineering | HNMT, SHMT1, TST | POLB 3901/4885ALPL 3279/4885ALPG 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.